Inclusion Criteria:  Age ≥ 18 years Understand the purpose of the trial, voluntarily participate in this study, and have signed an informed consent form. Patients with known or suspected CAD  Exclusion Criteria:  Patients with acute coronary syndrome. Severe cardiac dysfunction (LVEF ≤ 0.3). Cardiomyopathy with non-coronary causes such as hypertrophic cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy, and myocardial amyloidosis. Severe cardiac valve disease with more than moderate valvular regurgitation and/or valvular stenosis. Severe hepatic and renal dysfunction (ALT ≥ 3 Upper Limit of Normal, Cr> 134μ/mol/L (2mg/dl) or estimated Glomerular Filtration Rate<45ml/min/1.73m2). Severe arrhythmias (persistent atrial fibrillation, second-degree or third-degree atrioventricular block, etc.) Malignancy or other pathophysiological conditions with an expected survival of less than 1 year Allergic to the drug components involved in this study and those who are intolerant to loading tests Pregnant or lactating women. Mental disorders. Failure to sign the informed consent form. Other conditions that are incompatible with the clinical study.